transfers the methyl group from the O 6 -methylguanine to a Azoxymethane (AOM) causes O 6 -methylguanine adduct cysteine acceptor site in MGMT. This methylation of the formation which leads to G→A transitions. Their repair is MGMT cysteine residue prevents any further repair by the carried out by O 6 -methylguanine-DNA methyltransferase transferase and likely induces a conformational change leading (MGMT). To evaluate the importance of this repair event to rapid ubiquitin-mediated degradation (3). Since this reaction in AOM-induced carcinogenesis, we examined the effect of irreversibly inactivates the repair protein, the capacity for O 6 -benzylguanine (BG), a potent inhibitor of MGMT, on removal of methyl groups from these adducts depends on the colonic tumor development. Rats were treated weekly for number of active methyltransferase molecules.
weeks at 0 and 24 h with BG (60 mg/kg body wt i.p.) or
There is abundant evidence that MGMT regulates the toxic, vehicle (40% polyethylene glycol, PEG-400), followed 2 h mutagenic and carcinogenic potential of many alkylating after the first dose of BG with AOM (15 mg/kg body wt) agents. The direct toxic effect of these agents appears to or vehicle (saline) i.p. Rats were killed 35 weeks later and require ineffective DNA repair since this toxicity is inhibited, tumors harvested and DNA extracted. In the AOM-treated while tumorigenicity is enhanced, in mice lacking DNA groups, BG caused a significant increase in tumor incidence mismatch repair enzymes (4). That MGMT is required to with tumors in 65.9%, versus 30.8% in the AOM/PEGprevent O 6 -methylguanine-induced mutations has been directly treated group (P < 0.05). In the BG/AOM group there demonstrated by in vitro studies using CHO cells deficient in was also a significant increase in tumor multiplicity, with this repair protein (5). The role of MGMT in AOM-induced 2.3 tumors/tumor-bearing rat, versus 1.6 tumors/tumorexperimental colon cancer in rats has not previously been bearing rat in the AOM/PEG group (P < 0.05). Since O 6 -examined. Earlier studies, involving other alkylating agents, methylguanine adducts can cause activating mutations in were unable to demonstrate an effect of O 6 -benzylguanine the K-ras and β-catenin genes, we examined the effects of (BG), a potent inhibitor of MGMT, on hepatic tumor BG on these mutations. In the BG group there were seven incidence in rats despite a reduction in hepatic MGMT activity mutations in codon 12 or 13 of exon 1 of the K-ras gene (6). The present studies were, therefore, undertaken to address in 51 tumors examined, compared with no K-ras mutations the potential role of MGMT in AOM-induced colon cancer in in 17 tumors analyzed in the AOM/PEG group (P ⍧ 0.12).
rats. Since O 6 -methylguanine adducts induced by AOM have In the BG/AOM group there were 10 mutations in exon 3 previously been shown to cause G→A transitions, and ultiof the β-catenin gene among 48 tumors evaluated, compared mately activating mutations in β-catenin and K-ras genes, it with six mutations in 16 tumors analyzed in the PEG/AOM was also of interest to study the effect of BG on the mutational group (P ⍧ 0.16). In summary, MGMT inhibition increases status of these genes.
AOM-induced colonic tumor incidence and multiplicity
In initial studies we determined the kinetics of MGMT in rats.
inhibition in rat colonic tissue by BG, which was synthesized as described (7). Our goal was to significantly inhibit MGMT activity for at least 48 h, the duration of the rat colonic epithelial cell cycle, to prevent repair of an AOM-induced Colonic carcinogenesis is a multistep process involving the mutational event (8). The dose of BG (60 mg/kg body wt) progressive accumulation of activating mutations in protowas chosen to achieve maximum inhibition of MGMT without oncogenes and inactivating mutations in tumor suppressor compromising animal viability. Twenty-four Fisher 344 rats genes. Elucidation of genetic and epigenetic events are importreceived BG solubilized in polyethylene glycol (PEG) buffer ant both to enhance our understanding of malignant colonic (40% PEG in 10 mM sodium phosphate buffer, pH 7.4). PEG buffer is the standard diluent for BG (9) . A second injection the MGMT assay was performed as described previously (7). equal groups and given the following treatments at weeks 1 formalin fixation, tissue specimens were paraffin embedded, sectioned and stained with hematoxylin and eosin, as described previously (11). All specimens were evaluated by a pathologist To examine the effect of BG on O 6 -methylguanine adduct formation, 12 male Fisher 344 rats were divided into a control (J.H.) who was unaware of the treatment groups. Macroscopic lesions were classified as either benign (adenoma) or malignant and two treated groups of four rats each. For the treated groups, at time 0 four rats received BG (60 mg/kg body wt) (carcinoma in situ or adenocarcinoma) (12).
To investigate K-ras mutations in the first or second position and four rats received the standard diluent, PEG buffer. Two hours later each rat in the treated groups received AOM of codons 12, 13 and 59, a sequence from K-ras exon 1 (codons 12 and 13) or exon 2 (codon 59) was amplified (15 mg/kg body wt i.p.). Control and AOM ϩ BG-or AOM ϩ PEG-treated rats were killed 24 h after the AOM injection.
by PCR and probed for K-ras mutations by allele-specific oligonucleotide hybridization (ASOH) as described (13) . To Colonocyte DNA was extracted and the O 6 -and N 7 -methylguanine adducts measured as described (10).
confirm the ASOH results, we employed primer-mediated restriction fragment length polymorphism (PM-RFLP) for the Based on the time course for MGMT inhibition by BG, the following experimental design was used to assess the effect detection of K-ras mutations in codons 12 and 13 (14).
To assess mutations in CTNNB1, the gene coding for of MGMT inhibition on the development of AOM-induced colonic tumors. One hundred and twenty male Fisher 344 β-catenin, we employed single strand conformational polymorphism (SSCP) analysis after PCR amplification of exon 3 rats, initially weighing 80-100 g, were randomized into four Table III. AOM treatment, control and carcinogen-treated rats were a In the BG-AOM group, 51 of 66 tumors were evaluated for β-catenin and/ killed. Control colonocytes and tumors were harvested.
or K-ras mutations.
There were no significant differences in weight gain among b Not evaluated.
the rats treated with AOM ϩ BG or AOM ϩ PEG, compared with the control groups treated with PEG or BG alone (data not shown). There were no tumors that developed in the rats of this gene exactly as described (15). K-ras and β-catenin mutations were confirmed by direct sequencing of amplified receiving PEG or BG without carcinogen. In the carcinogentreated groups, however, BG significantly increased the tumor DNA using automated fluorescent DNA sequencing. Values were expressed as means Ϯ SEM. Differences between groups incidence, with tumors in 29 of 44 rats (65.9%), compared with only 12 of 39 rats with tumors (30.8%, P Ͻ 0.05) in the were compared by Fisher's exact test, with P Ͻ 0.05 considered statistically significant. group receiving PEG (Table II) . In addition, BG was associated with a significant increase in tumor multiplicity, with 66 tumors As shown in Table I , administration of BG abolished colonic MGMT activity for at least 48 h. By 72 h MGMT activity in in 29 rats, compared with 19 tumors in 12 rats (P Ͻ 0.05), i.e. 2.3 and 1.6 tumors/tumor-bearing rat, respectively (Table the colon had returned to pretreatment levels. In contrast, BG treatment failed to completely suppress liver MGMT activity, II). Histological examination of the tumors revealed no significant differences in the incidence of adenocarcinomas, which at baseline was Ͼ10-fold higher than that of colon. Based carcinoma in situ or adenomas between the two carcinogen-PEG ϩ AOM group, versus 248 Ϯ 49 µmol/mol guanine for treated groups (Tables III and IV) .
the BG ϩ AOM group (P Ͻ 0.05). These results confirmed AOM is known to cause O 6 -methylguanine adduct formathat BG did, indeed, increase AOM-induced O 6 -methylguanine tion in this experimental model which, if unrepaired by MGMT, adduct formation in rat colon. leads to G→A transitions and ultimately K-ras and β-catenin
As shown in Figure 3 , and summarized in Tables II-IV , mutations (15-17). Since BG inhibited colonic MGMT AOM was also found to induce mutations in β-catenin. The during tumor initiation, we speculated that this treatment might numbers of these mutations in the PEG/AOM (37.5%) and be associated with increased AOM-induced K-ras and/or β-BG/AOM (20.8%) groups were not significantly different catenin mutations. As shown in Figure 1 and Tables II-IV, (P ϭ 0.16). Surprisingly, however, in contrast to K-ras and as predicted, BG treatment was associated with a numerical mutations, there were numerically fewer β-catenin mutations increase in K-ras mutations, which were observed in seven of in the BG/AOM group. The incidences of β-catenin mutations 51 tumors examined (13.7% positive), compared with no in adenomas and carcinomas/carcinomas in situ were mutations found in 17 tumors from the carcinogen-treated comparable, occurring in 40 versus 27.1%, respectively group receiving PEG (P ϭ 0.12). Of the K-ras mutations, four (P ϭ 0.43). Of the total number of tumors assessed for occurred in codon 12, two in codon 13 and one tumor had both β-catenin and K-ras mutations, 44 were found to be mutations in both codons 12 and 13 (Table IV) . As shown in wild-type for both, 13 had β-catenin but not K-ras mutations, Figure 2 , the mutations identified by ASOH were all four had K-ras mutations but were wild-type for β-catenin confirmed by PM-RFLP (17), as well as by direct sequencing and in three tumors both mutations were present. There of the PCR products (data not shown). As in the case of were no significant statistical associations between these tumors with K-ras mutations, there was complete agreement mutations (P ϭ 0.23). between the ASOH and PM-RFLP techniques in identifying While MGMT has been demonstrated to play an important tumors expressing wild-type K-ras (Tables II-IV and Figures role in both the toxicity and tumorigenicity of alkylating agents 1 and 2). in other organs, using transgenic mice overexpressing this The absence of K-ras mutations in codons 12 and 13 in the protein (19-21), as well as knockout mice with MGMT gene AOM ϩ PEG-treated rats prompted us to screen for rarer interruption (22) (23) (24) , this is the first study to demonstrate the mutations involving K-ras codon 59 (13), but none were role of this repair protein in the development of colon cancer. found (data not shown). We reasoned that, in the absence of Previous studies with AOM in transgenic mice have only adequate MGMT activity during mutagenesis, G→A transitions examined the development of aberrant crypt foci, putative involving the first position of codons 12 or 13, causing precursors of malignancy (25) . Inhibition of colonic MGMT activating Gly→Ser substitutions, might also occur, although during the initiation phase of AOM colonic carcinogenesis these have not been reported in the AOM model of colonic was associated with more than a doubling of tumor incidence, carcinogenesis. As in the case of codon 59, however, no such as well as increased tumor multiplicity. The increased O 6 -mutations were identified (data not shown). The frequency of methylguanine adduct formation caused by AOM in the K-ras mutations in this study is similar to that of Vivona et al. presence of BG, compared with the AOM/PEG group, most (18), but lower than that reported in other studies (16, 17) likely accounts for the observed differences in tumorigenicity using comparable AOM treatment regimens. The explanation induced by these respective protocols (26) . for these differences is not apparent.
The specificity of AOM for the colon may, at least in part, We postulated that the increase in BG-associated, AOMreflect the relatively low abundance of MGMT in this organ induced tumors, compared with the AOM ϩ PEG-treated (27) compared with liver (Table I) , for example, as well as group, reflected an increase in O 6 -methylguanine adduct the presence of alcohol dehydrogenase in the colonic epithelium formation. To address this question we directly compared the (28) . Interestingly, low MGMT activity in human colonic effect of PEG versus BG on AOM-induced formation of O 6 -mucosa from individuals with colon cancer was associated methylguanine adducts. At 24 h, the mean of two independent with increased mutations in K-ras involving G→A transitions, determinations in duplicate of colonic O 6 -methylguanine adduct formation was 97 Ϯ 16 µmol/mol guanine for the but not G→C/T transversions, implying a role for derangements
Role of DNA repair in AOM-induced colon cancer 3. Srivenugopal,K.S., Yuan,X.H., Friedman,H.S. and Ali-Osman,F. (1996) in MGMT-induced O 6 -methylguanine adduct repair in a subset similar to the findings of others in the murine model (25) . We,
